Eli Lilly and Company (NYSE:LLY) Given Average Recommendation of “Moderate Buy” by Analysts

Eli Lilly and Company (NYSE:LLYGet Free Report) has earned a consensus rating of “Moderate Buy” from the nineteen brokerages that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and sixteen have assigned a buy rating to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $621.81.

A number of research firms have commented on LLY. Citigroup upped their price objective on shares of Eli Lilly and Company from $525.00 to $675.00 and gave the company a “buy” rating in a research note on Monday, October 23rd. UBS Group reissued a “buy” rating and issued a $710.00 price objective (up from $612.00) on shares of Eli Lilly and Company in a research report on Friday, October 20th. Wells Fargo & Company lifted their price objective on Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. Deutsche Bank Aktiengesellschaft assumed coverage on Eli Lilly and Company in a research report on Thursday, November 9th. They set a “hold” rating and a $535.00 target price for the company. Finally, Truist Financial boosted their target price on Eli Lilly and Company from $650.00 to $850.00 and gave the company a “buy” rating in a research note on Wednesday.

Check Out Our Latest Report on LLY

Insider Transactions at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of Eli Lilly and Company stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the transaction, the insider now directly owns 99,333,810 shares in the company, valued at $64,375,262,246.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold a total of 195,055 shares of company stock worth $125,254,657 in the last ninety days. Insiders own 0.13% of the company’s stock.

Institutional Investors Weigh In On Eli Lilly and Company

Several large investors have recently added to or reduced their stakes in LLY. Lipe & Dalton purchased a new stake in Eli Lilly and Company during the fourth quarter worth $26,000. Thompson Investment Management Inc. acquired a new stake in Eli Lilly and Company in the 3rd quarter valued at about $27,000. Retirement Group LLC raised its holdings in Eli Lilly and Company by 159.1% in the 2nd quarter. Retirement Group LLC now owns 57 shares of the company’s stock valued at $27,000 after acquiring an additional 35 shares during the last quarter. Tidemark LLC acquired a new stake in shares of Eli Lilly and Company during the 4th quarter worth approximately $29,000. Finally, Cornerstone Planning Group LLC acquired a new stake in Eli Lilly and Company in the 2nd quarter valued at approximately $33,000. 81.38% of the stock is owned by institutional investors.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $740.16 on Friday. Eli Lilly and Company has a 52 week low of $309.20 and a 52 week high of $745.70. The stock has a market cap of $702.64 billion, a price-to-earnings ratio of 127.61, a PEG ratio of 2.10 and a beta of 0.32. The company’s 50-day moving average price is $620.02 and its 200 day moving average price is $581.02. The company has a current ratio of 1.05, a quick ratio of 0.82 and a debt-to-equity ratio of 1.59.

Eli Lilly and Company (NYSE:LLYGet Free Report) last posted its earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 50.78%. The business had revenue of $9.35 billion for the quarter, compared to analysts’ expectations of $8.95 billion. During the same period in the previous year, the company posted $2.09 earnings per share. The business’s revenue for the quarter was up 28.1% compared to the same quarter last year. As a group, research analysts forecast that Eli Lilly and Company will post 12.52 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 8th. Stockholders of record on Thursday, February 15th will be paid a $1.30 dividend. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.13. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.70%. The ex-dividend date of this dividend is Wednesday, February 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is 77.93%.

Eli Lilly and Company Company Profile

(Get Free Report

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

See Also

Analyst Recommendations for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.